chufangao/CTO huggingface dataset:
Clinical trial NCT04026165: Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
Official title: MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects With Moderate to Advanced Diabetic Kidney Disease
Acronym: MOSAIC
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 384.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-24
Primary completion date: 2021-09-03
Completion date: 2021-09-03
Baseline population: The Safety Analysis Set included all participants who took at least 1 dose of Run-in SEL.
Plan to share individual participant data: NO
Clinical trial NCT04393597: Effects of Food on the Pharmacokinetics of DWJ1458 in Healthy Adults
Official title: A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics of Orally Administered DWJ1458 in Healthy Adults
Sponsor: Daewoong Pharmaceutical Co. LTD. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: We decided to discontinue this particular clinical study through internal discussion.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-28
Primary completion date: 2020-07-31
Completion date: 2020-11-30
Plan to share individual participant data: NO
Clinical trial NCT03073876: Detecting an Early Response to Donepezil With Measures of Visual Attention
Official title: Detecting an Early Response to Donepezil With Measures of Visual Attention
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2005-12-01
Primary completion date: 2009-07-31
Completion date: 2021-01-13
Plan to share individual participant data: NO
Clinical trial NCT04570436: Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
Official title: A Phase 4, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Single-dose, Five-way Crossover Study Evaluating the Abuse Potential of Three Doses of NEURONTIN® Taken Orally in Healthy, Non-drug Dependent Participants With Sedative Drug Abuse Experience
Sponsor: Viatris Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-03-29
Primary completion date: 2022-11-10
Completion date: 2022-11-10
Baseline population: All participants who completed all 5 treatment periods of the Treatment Phase, excluding those subjects who had scores for the primary endpoint (maximum Drug Liking Visual Analog Scale score) that were within 5 points across all 5 treatments and/or had high placebo scores for the primary endpoint (maximum Drug Liking Visual Analog Scale score for placebo was \> 60 on a 100 point scale and the primary endpoint for placebo was 5 or more points greater than that for the positive control, diazepam)
Plan to share individual participant data: NO
Clinical trial NCT01988779: Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations
Official title: Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-10-31
Primary completion date: 2017-09-11
Completion date: 2020-12-31
Clinical trial NCT04151719: An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Official title: An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
Sponsor: Bausch Health Americas, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Due to pandemic challenges and consideration of a different study design in the future.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-03
Primary completion date: 2024-02-03
Completion date: 2024-02-03
Clinical trial NCT04848220: A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous Coronary Intervention
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 29.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-20
Primary completion date: 2022-08-23
Completion date: 2022-08-31
Baseline population: Full analysis set (FAS) included all randomized participants, irrespective of whether they received any study treatment.
Limitations and caveats: This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04371107: Proactive Care of Ambulatory COVID19 Patients
Official title: Proactive Care of Ambulatory COVID19 Patients: Open-labeled Randomized Trial
Acronym: AMBU-COVID
Sponsor: Centre Hospitalier Universitaire, Amiens (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: ANSM notifications
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-29
Primary completion date: 2020-06-01
Completion date: 2023-07-01
Plan to share individual participant data: NO
Clinical trial NCT04371185: Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
Official title: A Randomized, Double-blinded, Single-dose, 3-arms Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2206 Injection vs Ustekinumab Injection (Stelara) in Healthy Chinese Male Subjects
Sponsor: Bio-Thera Solutions (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 270.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-08
Primary completion date: 2021-04-19
Completion date: 2021-04-19
Plan to share individual participant data: NO
IPD sharing description: Only one site study
Clinical trial NCT02684058: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Official title: Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 151.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-28
Primary completion date: 2021-08-23
Completion date: 2023-04-28
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04592159: Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder
Official title: A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: The decision to suspend this study was based upon evaluation of pandemic-related challenges impacting both clinical trial sites and potential participants. This suspension was initiated prior to site activation and participant recruitment.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT03221166: Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
Official title: Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network
Sponsor: IRCCS Burlo Garofolo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Difficulty in recruiting subjects who meet the inclusion/exclusion criteria
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-27
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Plan to share individual participant data: NO
Clinical trial NCT02295501: A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
Official title: A Prospective, Open Label Observational, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
Sponsor: Cerus Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated on expiry of the frozen and stored plasma components.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-12-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04657666: Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Official title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis
Acronym: RELEASE MSS1
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-21
Primary completion date: 2022-05-04
Completion date: 2022-05-10
Baseline population: Baseline demographics were assessed in the Full Analysis Set.
Plan to share individual participant data: NO
Clinical trial NCT02955212: A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 338.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-03
Primary completion date: 2019-08-14
Completion date: 2020-09-03
Baseline population: The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT01974440: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Acronym: SELENE
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 403.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-01-31
Primary completion date: 2022-05-30
Completion date: 2023-06-21
Clinical trial NCT04987762: Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
Official title: An Open-Label, Multicenter, Multiple-Dose, Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children 4 to 12 Years of Age
Sponsor: Purdue Pharma LP (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: due to administrative reasons not related to efficacy or safety.
Enrollment: 103.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-03
Primary completion date: 2022-04-27
Completion date: 2022-04-27
Limitations and caveats: Study terminated early - only safety data collected until termination are presented.
Plan to share individual participant data: NO
Clinical trial NCT05191472: Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Official title: Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low Accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-03
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT05694013: Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
Official title: Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization in Participants Receiving Systemic Treatment in Clinical Practice
Acronym: ORIGAMA
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Study terminated by sponsor.
Enrollment: 49.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-02-27
Primary completion date: 2024-07-04
Completion date: 2024-07-04
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT05411575: Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)
Official title: A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19.
Acronym: LEONARDO
Sponsor: 4P-Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-19
Primary completion date: 2022-10-31
Completion date: 2022-10-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03644342: Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix
Official title: Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix
Acronym: NIVIX
Sponsor: Baylor College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: A recent change in treatment landscape may make study futile
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-15
Primary completion date: 2022-04-18
Completion date: 2023-09-27
Plan to share individual participant data: NO
Clinical trial NCT04964050: A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions
Official title: An Open-label, Randomized Three Period, Three Sequence, Partially Replicated Crossover Bioequivalence Study of Two Oral Formulations of Captopril/Hydrochlorothiazide 50/25 mg Tablets in Healthy Adult Participants Under Fasting Conditions
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Internal sponsor decision to terminate project prematurely based on a waiver granted by Egypt EDA (Egyptian drug authority). No subjects were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-04-21
Primary completion date: 2022-05-26
Completion date: 2022-05-26
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03925675: 18F-Fluciclovine PET and Multiparametric MR Imaging
Official title: Differentiating Brain Tumor Recurrence From Treatment-Induced Necrosis Using 18F-Fluciclovine (Anti-18f-facbc) PET and Multiparametric MR Imaging
Sponsor: Loma Linda University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No subjects enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-24
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT05215951: Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
Official title: The Efficacy and Safety of Osimertinib With Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Advanced Non-small Cell Lung Cancer Patients With Uncommon Epidermal Growth Factor Receptor Mutations: A phase2, Open Label, Single Arm, Multicenter, Exploratory Study
Acronym: MINOVA
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment delay study timeline seriously.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-06
Primary completion date: 2023-03-09
Completion date: 2023-03-09
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03750760: Early Alirocumab to Reduce LDL-C in Myocardial Infarction
Official title: Early Alirocumab to Reduce LDL-C in Myocardial Infarction
Acronym: EARLY
Sponsor: Imperial College London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Changes in funding decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2020-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02685735: Predicting, Understanding and Speeding Recovery After TKA
Official title: Predicting, Understanding, and Speeding Recovery After Total Knee Arthroplasty
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: lack of continued funding support
Enrollment: 350.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-02
Primary completion date: 2022-02-09
Completion date: 2022-02-09
Limitations and caveats: The trial was terminated early because of depletion of funding. Power analysis was based on 250 subjects and only 208 (83% of proposed total) were studied before termination of funding.
Plan to share individual participant data: NO
Clinical trial NCT02805894: NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
Official title: A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation
Sponsor: Nanobiotix (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-15
Primary completion date: 2020-03-19
Completion date: 2020-03-19
Plan to share individual participant data: NO